A population-based cohort study in Taiwan--use of insulin sensitizers can decrease cancer risk in diabetic patients? (Q38429541)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

title

A population-based cohort study in Taiwan--use of insulin sensitizers can decrease cancer risk in diabetic patients? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

population-based cohort study

16 February 2020

main subject

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

author name string

C-H Kao

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

L-M Sun

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

M-C Lin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

J-A Liang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

C-H Muo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

S-N Chang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

F-C Sung

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

publication date

30 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

523-530

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23110810 AND SRC:MED&resulttype=core&format=json

Troglitazone and related compounds: therapeutic potential beyond diabetes

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Does universal health insurance make health care unaffordable? Lessons from Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

The association between malignancy and end-stage renal disease in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Diabetes, insulin, and risk of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

The many faces of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Diabetes mellitus correlates with increased risk of pancreatic cancer: A population‐based cohort study in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472

Epidemiologic study of type 2 diabetes in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS472